The DOI matches its Crossref record; 94 of the 94 references it cites were found in a registry or an index.
Pre-existing immunity against Ad vectors: Humoral, cellular, and innate response, what's important?
Open accessAbstract
Pre-existing immunity against human adenovirus (HAd) serotype 5 derived vector in the human population is widespread, thus hampering its clinical use. Various components of the immune system, including neutralizing antibodies (nAbs), Ad specific T cells and type I IFN activated NK cells, contribute to dampening the efficacy of Ad vectors in individuals with pre-existing Ad immunity. In order to circumvent pre-existing immunity to adenovirus, numerous strategies, such as developing alternative Ad serotypes, varying immunization routes and utilizing prime-boost regimens, are under pre-clinical or clinical phases of development. However, these strategies mainly focus on one arm of pre-existing immunity. Selection of alternative serotypes has been largely driven by the absence in the human population of nAbs against them with little attention paid to cross-reactive Ad specific T cells. Conversely, varying the route of immunization appears to mainly rely on avoiding Ad specific tissue-resident T cells. Finally, prime-boost regimens do not actually circumvent pre-existing immunity but instead generate immune responses of sufficient magnitude to confer protection despite pre-existing immunity. Combining the above strategies and thus taking into account all components regulating pre-existing Ad immunity will help further improve the development of Ad vectors for animal and human use.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Buchbinder, S. P., Mehrotra, D. V., Duerr, A., Fitzgerald, D. W., Mogg, R., Li, D., Gilbert, P. B., Lama, J. R., Marmor, M., del Rio, C., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61591-3 · Cited by 1,713
Raper, S. E., Chirmule, N., Lee, F. S., Wivel, N. A., Bagg, A., Gao, G.-P., Wilson, J. M., & Batshaw, M. L. (2003) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2003.08.016 · Cited by 1,498
Monoclonal antibodies: versatile platforms for cancer immunotherapy
Weiner, L. M., Surana, R., & Wang, S. (2010) · Nature Reviews Immunology · doi:10.1038/nri2744 · Cited by 1,283
Gebhardt, T., Wakim, L. M., Eidsmo, L., Reading, P. C., Heath, W. R., & Carbone, F. R. (2009) · Nature Immunology · doi:10.1038/ni.1718 · Cited by 1,157
T cell– and B cell–independent adaptive immunity mediated by natural killer cells
O'Leary, J. G., Goodarzi, M., Drayton, D. L., & von Andrian, U. H. (2006) · Nature Immunology · doi:10.1038/ni1332 · Cited by 919
Skin infection generates non-migratory memory CD8+ TRM cells providing global skin immunity
Jiang, X., Clark, R. A., Liu, L., Wagers, A. J., Fuhlbrigge, R. C., & Kupper, T. S. (2012) · Nature · doi:10.1038/nature10851 · Cited by 891
Cytokine-induced memory-like natural killer cells
Cooper, M. A., Elliott, J. M., Keyel, P. A., Yang, L., Carrero, J. A., & Yokoyama, W. M. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813192106 · Cited by 831
Immune responses to adenovirus and adeno-associated virus in humans
Chirmule, N., Propert, K. J., Magosin, S. A., Qian, Y., Qian, R., & Wilson, J. M. (1999) · Gene Therapy · doi:10.1038/sj.gt.3300994 · Cited by 684
Adenoviruses as vaccine vectors
Tatsis, N., & Ertl, H. C. J. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2004.07.013 · Cited by 669
Mackay, L. K., Stock, A. T., Ma, J. Z., Jones, C. M., Kent, S. J., Mueller, S. N., Heath, W. R., Carbone, F. R., & Gebhardt, T. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1202288109 · Cited by 635
Measles Antibody: Reevaluation of Protective Titers
Chen, R. T., Markowitz, L. E., Albrecht, P., Stewart, J. A., Mofenson, L. M., Preblud, S. R., & Orenstein, W. A. (1990) · Journal of Infectious Diseases · doi:10.1093/infdis/162.5.1036 · Cited by 608
Gene therapy clinical trials worldwide to 2007—an update
Edelstein, M. L., Abedi, M. R., & Wixon, J. (2007) · The Journal of Gene Medicine · doi:10.1002/jgm.1100 · Cited by 584
Antibody Therapeutics in Cancer
Sliwkowski, M. X., & Mellman, I. (2013) · Science · doi:10.1126/science.1241145 · Cited by 543
Different patterns of peripheral migration by memory CD4+ and CD8+ T cells
Gebhardt, T., Whitney, P. G., Zaid, A., Mackay, L. K., Brooks, A. G., Heath, W. R., Carbone, F. R., & Mueller, S. N. (2011) · Nature · doi:10.1038/nature10339 · Cited by 529
Adenoviruses in Immunocompromised Hosts
Echavarría, M. (2008) · Clinical Microbiology Reviews · doi:10.1128/cmr.00052-07 · Cited by 512
Abbink, P., Lemckert, A. A. C., Ewald, B. A., Lynch, D. M., Denholtz, M., Smits, S., Holterman, L., Damen, I., Vogels, R., Thorner, A. R., et al. (2007) · Journal of Virology · doi:10.1128/jvi.02696-06 · Cited by 503
Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity
Roberts, D. M., Nanda, A., Havenga, M. J. E., Abbink, P., Lynch, D. M., Ewald, B. A., Liu, J., Thorner, A. R., Swanson, P. E., Gorgone, D. A., et al. (2006) · Nature · doi:10.1038/nature04721 · Cited by 491
Heterologous prime-boost vaccination
Lu, S. (2009) · Current Opinion in Immunology · doi:10.1016/j.coi.2009.05.016 · Cited by 481
Vogels, R., Zuijdgeest, D., van Rijnsoever, R., Hartkoorn, E., Damen, I., de Béthune, M.-P., Kostense, S., Penders, G., Helmus, N., Koudstaal, W., et al. (2003) · Journal of Virology · doi:10.1128/jvi.77.15.8263-8271.2003 · Cited by 467
Novel Adenovirus-Based Vaccines Induce Broad and Sustained T Cell Responses to HCV in Man
Barnes, E., Folgori, A., Capone, S., Swadling, L., Aston, S., Kurioka, A., Meyer, J., Huddart, R., Smith, K., Townsend, R., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003155 · Cited by 405
Gray, G. E., Allen, M., Moodie, Z., Churchyard, G., Bekker, L.-G., Nchabeleng, M., Mlisana, K., Metch, B., de Bruyn, G., Latka, M. H., et al. (2011) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70098-6 · Cited by 387
Barouch, D. H., Pau, M. G., Custers, J. H. H. V., Koudstaal, W., Kostense, S., Havenga, M. J. E., Truitt, D. M., Sumida, S. M., Kishko, M. G., Arthur, J. C., et al. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.10.6290 · Cited by 383
Sumida, S. M., Truitt, D. M., Lemckert, A. A. C., Vogels, R., Custers, J. H. H. V., Addo, M. M., Lockman, S., Peter, T., Peyerl, F. W., Kishko, M. G., et al. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.11.7179 · Cited by 369
Zhu, J., Huang, X., & Yang, Y. (2007) · Journal of Virology · doi:10.1128/jvi.02192-06 · Cited by 366
Jump-starting the immune system: prime–boosting comes of age
Woodland, D. L. (2004) · Trends in Immunology · doi:10.1016/j.it.2003.11.009 · Cited by 346
Colloca, S., Barnes, E., Folgori, A., Ammendola, V., Capone, S., Cirillo, A., Siani, L., Naddeo, M., Grazioli, F., Esposito, M. L., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3002925 · Cited by 300
Mast, T. C., Kierstead, L., Gupta, S. B., Nikas, A. A., Kallas, E. G., Novitsky, V., Mbewe, B., Pitisuttithum, P., Schechter, M., Vardas, E., et al. (2010) · Vaccine · doi:10.1016/j.vaccine.2009.10.145 · Cited by 276
Nwanegbo, E., Vardas, E., Gao, W., Whittle, H., Sun, H., Rowe, D., Robbins, P. D., & Gambotto, A. (2004) · Clinical and Vaccine Immunology · doi:10.1128/cdli.11.2.351-357.2004 · Cited by 266
Hartman, Z. C., Appledorn, D. M., & Amalfitano, A. (2008) · Virus Research · doi:10.1016/j.virusres.2007.10.005 · Cited by 239
Gall, J., Kass-Eisler, A., Leinwand, L., & Falck-Pedersen, E. (1996) · Journal of Virology · doi:10.1128/jvi.70.4.2116-2123.1996 · Cited by 239
Geisbert, T. W., Bailey, M., Hensley, L., Asiedu, C., Geisbert, J., Stanley, D., Honko, A., Johnson, J., Mulangu, S., Pau, M. G., et al. (2011) · Journal of Virology · doi:10.1128/jvi.02407-10 · Cited by 224
Ledgerwood, J. E., Costner, P., Desai, N., Holman, L., Enama, M. E., Yamshchikov, G., Mulangu, S., Hu, Z., Andrews, C. A., Sheets, R. A., et al. (2010) · Vaccine · doi:10.1016/j.vaccine.2010.10.037 · Cited by 210
Di Paolo, N. C., Miao, E. A., Iwakura, Y., Murali-Krishna, K., Aderem, A., Flavell, R. A., Papayannopoulou, T., & Shayakhmetov, D. M. (2009) · Immunity · doi:10.1016/j.immuni.2009.04.015 · Cited by 207
Overcoming Immunity to a Viral Vaccine by DNA Priming before Vector Boosting
Yang, Z.-Y., Wyatt, L. S., Kong, W.-P., Moodie, Z., Moss, B., & Nabel, G. J. (2003) · Journal of Virology · doi:10.1128/jvi.77.1.799-803.2003 · Cited by 204
Xiang, Z., Gao, G., Reyes-Sandoval, A., Cohen, C. J., Li, Y., Bergelson, J. M., Wilson, J. M., & Ertl, H. C. J. (2002) · Journal of Virology · doi:10.1128/jvi.76.6.2667-2675.2002 · Cited by 195
McCoy, K., Tatsis, N., Korioth-Schmitz, B., Lasaro, M. O., Hensley, S. E., Lin, S.-W., Li, Y., Giles-Davis, W., Cun, A., Zhou, D., et al. (2007) · Journal of Virology · doi:10.1128/jvi.02497-06 · Cited by 185
Reyes-Sandoval, A., Berthoud, T., Alder, N., Siani, L., Gilbert, S. C., Nicosia, A., Colloca, S., Cortese, R., & Hill, A. V. S. (2010) · Infection and Immunity · doi:10.1128/iai.00740-09 · Cited by 176
Sumida, S. M., Truitt, D. M., Kishko, M. G., Arthur, J. C., Jackson, S. S., Gorgone, D. A., Lifton, M. A., Koudstaal, W., Pau, M. G., Kostense, S., et al. (2004) · Journal of Virology · doi:10.1128/jvi.78.6.2666-2673.2004 · Cited by 171
Baden, L. R., Walsh, S. R., Seaman, M. S., Tucker, R. P., Krause, K. H., Patel, A., Johnson, J. A., Kleinjan, J., Yanosick, K. E., Perry, J., et al. (2013) · The Journal of Infectious Diseases · doi:10.1093/infdis/jis670 · Cited by 166
Yellow Fever Vaccine: Direct Challenge of Monkeys Given Graded Doses of 17D Vaccine
Mason, R. A., Tauraso, N. M., Spertzel, R. O., & Ginn, R. K. (1973) · Applied Microbiology · doi:10.1128/aem.25.4.539-544.1973 · Cited by 165
Coagulation Factor X Activates Innate Immunity to Human Species C Adenovirus
Doronin, K., Flatt, J. W., Di Paolo, N. C., Khare, R., Kalyuzhniy, O., Acchione, M., Sumida, J. P., Ohto, U., Shimizu, T., Akashi-Takamura, S., et al. (2012) · Science · doi:10.1126/science.1226625 · Cited by 165
Lemckert, A. A. C., Sumida, S. M., Holterman, L., Vogels, R., Truitt, D. M., Lynch, D. M., Nanda, A., Ewald, B. A., Gorgone, D. A., Lifton, M. A., et al. (2005) · Journal of Virology · doi:10.1128/jvi.79.15.9694-9701.2005 · Cited by 159
Roy, S., Vandenberghe, L. H., Kryazhimskiy, S., Grant, R. L., Calcedo, R., Yuan, X., Keough, M. P., Sandhu, A., Wang, Q., Medina-Jaszek, C. A., et al. (2009) · PLoS Pathogens · doi:10.1371/journal.ppat.1000503 · Cited by 158
Key Role of Splenic Myeloid DCs in the IFN-αβ Response to Adenoviruses In Vivo
Fejér, G., Drechsel, L., Liese, J., Schleicher, U., Ruzsics, Z., Imelli, N., Greber, U. F., Keck, S., Hildenbrand, B., Krug, A., et al. (2008) · PLoS Pathogens · doi:10.1371/journal.ppat.1000208 · Cited by 148
Adenovirus-Based Vaccines: Comparison of Vectors from Three Species of Adenoviridae
Chen, H., Xiang, Z., Li, Y., Kurupati, R. K., Jia, B., Bian, A., Zhou, D., Hutnick, N. A., Yuan, S., Gray, C., et al. (2010) · Journal of Virology · doi:10.1128/jvi.00450-10 · Cited by 148
Development of nonhuman adenoviruses as vaccine vectors
Bangari, D. S., & Mittal, S. K. (2005) · Vaccine · doi:10.1016/j.vaccine.2005.08.101 · Cited by 145
Leen, A. M., Sili, U., Vanin, E. F., Jewell, A. M., Xie, W., Vignali, D. A. A., Piedra, P. A., Brenner, M. K., & Rooney, C. M. (2004) · Blood · doi:10.1182/blood-2004-02-0646 · Cited by 143
Identification of Hexon-Specific CD4 and CD8 T-Cell Epitopes for Vaccine and Immunotherapy
Leen, A. M., Christin, A., Khalil, M., et al. (2007) · Journal of Virology · doi:10.1128/jvi.01689-07 · Cited by 141
Xiang, Z., Gao, G., Reyes‐Sandoval, A., Li, Y., Wilson, J. M., & Ertl, H. C. J. (2003) · Journal of Virology · doi:10.1128/jvi.77.20.10780-10789.2003 · Cited by 140
Teigler, J. E., Iampietro, M. J., & Barouch, D. H. (2012) · Journal of Virology · doi:10.1128/jvi.00740-12 · Cited by 128
Characterization of Human Proliferative T Cell Responses to Adenovirus
Flomenberg, P. R., Piaskowski, V. D., Truitt, R. L., & Casper, J. T. (1995) · The Journal of Infectious Diseases · doi:10.1093/infdis/171.5.1090 · Cited by 127
Chimpanzee adenovirus vaccine protects against Zaire Ebola virus
Kobinger, G., Feldmann, H., Zhi, Y., Schumer, G., Gao, G., Feldmann, F., Jones, S. J. M., & Wilson, J. M. (2005) · Virology · doi:10.1016/j.virol.2005.10.042 · Cited by 126
Self-citationAdenovirus and adeno-associated virus mediated gene transfer
Kremer, E. J., & Perricaudet, M. (1995) · British Medical Bulletin · doi:10.1093/oxfordjournals.bmb.a072951 · Cited by 123
Barouch, D. H., McKay, P. F., Sumida, S. M., Santra, S., Jackson, S. S., Gorgone, D. A., Lifton, M. A., Chakrabarti, B. K., Xu, L., Nabel, G. J., et al. (2003) · Journal of Virology · doi:10.1128/jvi.77.16.8729-8735.2003 · Cited by 122
Barouch, D. H., Liu, J., Peter, L. E., Abbink, P., Iampietro, M. J., Cheung, A., Alter, G., Chung, A. W., Dugast, A., Frahm, N., et al. (2012) · The Journal of Infectious Diseases · doi:10.1093/infdis/jis671 · Cited by 118
The Adenovirus Capsid Protein Hexon Contains a Highly Conserved Human CD4 + T-Cell Epitope
Olive, M., Eisenlohr, L. C., Flomenberg, N., Hsu, S. H., & Flomenberg, P. R. (2002) · Human Gene Therapy · doi:10.1089/104303402320138952 · Cited by 117
Antipeptide antisera define neutralizing epitopes on the adenovirus hexon
Toogood, C. I. A., Crompton, J. L., & Hay, R. T. (1992) · Journal of General Virology · doi:10.1099/0022-1317-73-6-1429 · Cited by 117
Structure-Based Identification of a Major Neutralizing Site in an Adenovirus Hexon
Pichla-Gollon, S. L., Drinker, M. S., Zhou, X., Xue, F., Rux, J. J., Gao, G., Wilson, J. M., Ertl, H. C. J., Burnett, R. M., & Bergelson, J. M. (2006) · Journal of Virology · doi:10.1128/jvi.02023-06 · Cited by 115
Pinto, A. R., Fitzgerald, J. C., Giles‐Davis, W., Gao, G. P., Wilson, J. M., & Ertl, H. C. J. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.12.6774 · Cited by 113
Circumvention of Immunity to the Adenovirus Major Coat Protein Hexon
Roy, S., Shirley, P. S., McClelland, A., & Kaleko, M. (1998) · Journal of Virology · doi:10.1128/jvi.72.8.6875-6879.1998 · Cited by 111
The Challenge for Gene Therapy: Innate Immune Response to Adenoviruses
Thaçi, B., Ulasov, I. V., Wainwright, D. A., & Lesniak, M. S. (2011) · Oncotarget · doi:10.18632/oncotarget.231 · Cited by 109
Ovine Adenovirus Vectors Overcome Preexisting Humoral Immunity against Human Adenoviruses In Vivo
Hofmann, C., Löser, P., Cichon, G., Arnold, W., Both, G. W., & Strauss, M. (1999) · Journal of Virology · doi:10.1128/jvi.73.8.6930-6936.1999 · Cited by 108
Kibuuka, H. N., Kimutai, R., Maboko, L., Sawe, F. K., Schunk, M., Kroidl, A., Shaffer, D., Eller, L. A., Kibaya, R. M., Eller, M. A., et al. (2010) · The Journal of Infectious Diseases · doi:10.1086/650299 · Cited by 106
Moffatt, S., Hays, J. P., HogenEsch, H., & Mittal, S. K. (2000) · Virology · doi:10.1006/viro.2000.0350 · Cited by 100
Protective immunity following vaccination: How is it defined?
Amanna, I. J., Messaoudi, I., & Slifka, M. K. (2008) · Human Vaccines · doi:10.4161/hv.4.4.5751 · Cited by 92
Peripheral tissue surveillance and residency by memory T cells
Gebhardt, T., Mueller, S. N., Heath, W. R., & Carbone, F. R. (2012) · Trends in Immunology · doi:10.1016/j.it.2012.08.008 · Cited by 92
Reyes‐Sandoval, A., Sridhar, S., Berthoud, T. K., Moore, A., Harty, J. T., Gilbert, S. C., Gao, G., Ertl, H. C. J., Wilson, J. M., & Hill, A. V. S. (2008) · European Journal of Immunology · doi:10.1002/eji.200737672 · Cited by 92
Zhu, J., Huang, X., & Yang, Y. (2008) · Molecular Therapy · doi:10.1038/mt.2008.88 · Cited by 90
Heemskerk, B., Veltrop‐Duits, L. A., van Vreeswijk, T., ten Dam, M. M., Heidt, S., Toes, R. E. M., van Tol, M. J. D., & Schilham, M. W. (2003) · Journal of Virology · doi:10.1128/jvi.77.11.6562-6566.2003 · Cited by 90
Nanda, A., Lynch, D. M., Goudsmit, J., Lemckert, A. A. C., Ewald, B. A., Sumida, S. M., Truitt, D. M., Abbink, P., Kishko, M., Gorgone, D. A., et al. (2005) · Journal of Virology · doi:10.1128/jvi.79.22.14161-14168.2005 · Cited by 88
Keefer, M. C., Gilmour, J. W., Hayes, P., Gill, D. K., Kopycinski, J. T., Cheeseman, H. M., Cashin‐Cox, M., Naarding, M. A., Clark, L., Fernández, N., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0041936 · Cited by 87
Capone, S., D’Alise, A. M., Ammendola, V., Colloca, S., Cortese, R., Nicosia, A., & Folgori, A. (2013) · Expert Review of Vaccines · doi:10.1586/erv.13.15 · Cited by 87
Human CD8+ cytotoxic T cell responses to adenovirus capsid proteins
Tang, J., Olive, M., Pulmanausahakul, R., Schnell, M. J., Flomenberg, N., Eisenlohr, L. C., & Flomenberg, P. R. (2006) · Virology · doi:10.1016/j.virol.2006.01.024 · Cited by 83
NK cells controlling virus-specific T cells: rheostats for acute vs. persistent infections
Welsh, R., & Waggoner, S. (2013) · Virology · doi:10.1016/j.virol.2012.10.005 · Cited by 79
Type I interferon inhibits antibody responses induced by a chimpanzee adenovirus vector.
Hensley, S. E., Cun, A. S., Giles-Davis, W., Li, Y., Xiang, Z., Lasaro, M. O., Williams, B. R. G., Silverman, R. H., & Ertl, H. C. J. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300024 · Cited by 78
Singh, N., Pandey, A., Jayashankar, L., & Mittal, S. K. (2008) · Molecular Therapy · doi:10.1038/mt.2008.12 · Cited by 78
Richardson, J. S., Pillet, S., Bello, A., & Kobinger, G. (2013) · Journal of Virology · doi:10.1128/jvi.02864-12 · Cited by 74
Self-citationHensley, S. E., Giles‐Davis, W., McCoy, K. C., Weninger, W., & Ertl, H. C. J. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.9.6032 · Cited by 73
Gudmundsdotter, L., Nilsson, C., Bråve, A., Hejdeman, B., Earl, P. L., Moss, B., Robb, M., Cox, J. H., Michael, N. L., Marovich, M., et al. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.05.018 · Cited by 72
Host Immune Responses to Chronic Adenovirus Infections in Human and Nonhuman Primates
Calcedo, R., Vandenberghe, L. H., Roy, S., Somanathan, S., Wang, L., & Wilson, J. M. (2008) · Journal of Virology · doi:10.1128/jvi.02160-08 · Cited by 68
Pichla-Gollon, S. L., Lin, S., Hensley, S. E., Lasaro, M. O., Haut, L. H., Drinker, M. S., Tatsis, N., Gao, G., Wilson, J. M., Ertl, H. C. J., et al. (2009) · Journal of Virology · doi:10.1128/jvi.00405-09 · Cited by 66
Bangari, D. S., Shukla, S., & Mittal, S. K. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.12.099 · Cited by 63
Protection of non-human primates against rabies with an adenovirus recombinant vaccine
Xiang, Z., Greenberg, L., Ertl, H. C. J., & Rupprecht, C. E. (2014) · Virology · doi:10.1016/j.virol.2013.12.029 · Cited by 61
Zhou, D., Cun, A., Li, Y., Xiang, Z., & Ertl, H. C. J. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.03.027 · Cited by 57
Rahman, A., Tsai, V., Goudreau, A., et al. (2001) · Molecular Therapy · doi:10.1006/mthe.2001.0316 · Cited by 50
Sharma, A., Tandon, M., Ahi, Y. S., Bangari, D. S., Vemulapalli, R., & Mittal, S. K. (2010) · Gene Therapy · doi:10.1038/gt.2010.1 · Cited by 49
Park, S., Yang, S.-H., Lee, C. G., Youn, J., Chang, J., & Sung, Y. C. (2003) · Vaccine · doi:10.1016/s0264-410x(03)00499-7 · Cited by 46
Richardson, J. S., Abou, M., Tran, K. N., Kumar, A., Sahai, B. M., & Kobinger, G. (2011) · The Journal of Infectious Diseases · doi:10.1093/infdis/jir332 · Cited by 43
Self-citationAdenovirus-triggered innate signalling pathways
Fejér, G., Freudenberg, M. A., Greber, U. F., & Győry, I. (2011) · European Journal of Microbiology and Immunology · doi:10.1556/eujmi.1.2011.4.3 · Cited by 42
Use of chimeric adenoviral vectors to assess capsid neutralization determinants
Roy, S., Clawson, D. S., Calcedo, R., Lebherz, C., Sanmiguel, J. C., Wu, D., & Wilson, J. M. (2005) · Virology · doi:10.1016/j.virol.2004.12.029 · Cited by 38
Patel, A. R., Tikoo, S. K., & Kobinger, G. (2010) · PLoS ONE · doi:10.1371/journal.pone.0015301 · Cited by 26
Self-citationJohnson, M. J., Björkström, N. K., Petrovas, C., Liang, F., Gall, J. G. D., Loré, K., & Koup, R. A. (2013) · Vaccine · doi:10.1016/j.vaccine.2013.11.055 · Cited by 22
Tissue Competence Imprinting and Tissue Residency of CD8 T Cells
Krzysiek, R., de Herve, M.-G. D. G., Yang, H., & Taoufik, Y. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00283 · Cited by 19
Li, J., Zhao, Q., Zhang, S., Huang, W., Xiong, Y., Zhou, X., & Jia, B. (2013) · Archives of Virology · doi:10.1007/s00705-013-1828-y · Cited by 11
Cited by
SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates
Kyriakidis, N. C., López-Cortés, A., González, E. V., Grimaldos, A. B., & Prado, E. O. (2021) · npj Vaccines · doi:10.1038/s41541-021-00292-w · Cited by 698
COVID-19 vaccine development and a potential nanomaterial path forward
Shin, M. D., Shukla, S., Chung, Y. H., Beiss, V., Chan, S. K., Ortega-Rivera, O. A., Wirth, D. M., Chen, A., Sack, M., Pokorski, J. K., et al. (2020) · Nature Nanotechnology · doi:10.1038/s41565-020-0737-y · Cited by 659
New Vaccine Technologies to Combat Outbreak Situations
Rauch, S., Jasny, E., Schmidt, K. E., & Petsch, B. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01963 · Cited by 579
Coronavirus vaccine development: from SARS and MERS to COVID-19
Li, Y.-D., Chi, W.-Y., Su, J.-H., Ferrall, L., Hung, C.-F., & Wu, T.-C. (2020) · Journal of Biomedical Science · doi:10.1186/s12929-020-00695-2 · Cited by 453
Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis, therapeutics and vaccines
Fernandes, Q., Inchakalody, V. P., Merhi, M., Mestiri, S., Taib, N., Moustafa Abo El-Ella, D., Bedhiafi, T., Raza, A., Al-Zaidan, L., Mohsen, M. O., et al. (2022) · Annals of Medicine · doi:10.1080/07853890.2022.2031274 · Cited by 447
Metadata
- Authors
- Fausther-Bovendo, H., & Kobinger, G. P.
- Venue
- Human Vaccines & Immunotherapeutics
- Publisher
- Informa UK Limited
- Published
- 2014-10-03
- Volume
- 10
- Issue
- 10
- Pages
- 2875-2884
- ISSN
- 2164-5515 (ISSN-L)
- 2164-554X
- OpenAlex
- W1557780170
- Cited by
- 276
- References
- 94
- FWCI
- 2.97
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.